Similar articles for PMID: 32152527

Year	Number of Results
2003	1
2005	3
2007	1
2008	4
2009	1
2010	4
2011	3
2012	5
2013	3
2014	7
2015	11
2016	10
2017	11
2018	15
2019	15
2020	7
2021	5
2022	6
2023	1
2024	0

1

Antibiotics in the clinical pipeline in October 2019.

Butler MS, Paterson DL. Butler MS, et al. J Antibiot (Tokyo). 2020 Jun;73(6):329-364. doi: 10.1038/s41429-020-0291-8. Epub 2020 Mar 10. J Antibiot (Tokyo). 2020. PMID: 32152527 Free PMC article. Review.

2

Multidrug-resistant gram-negative organisms: a review of recently approved antibiotics and novel pipeline agents.

Provenzani A, Hospodar AR, Meyer AL, Leonardi Vinci D, Hwang EY, Butrus CM, Polidori P. Provenzani A, et al. Int J Clin Pharm. 2020 Aug;42(4):1016-1025. doi: 10.1007/s11096-020-01089-y. Epub 2020 Jul 7. Int J Clin Pharm. 2020. PMID: 32638294 Review.

3

Antibiotics in the clinical pipeline in 2011.

Butler MS, Cooper MA. Butler MS, et al. J Antibiot (Tokyo). 2011 Jun;64(6):413-25. doi: 10.1038/ja.2011.44. Epub 2011 May 18. J Antibiot (Tokyo). 2011. PMID: 21587262 Review.

4

Developments on antibiotics for multidrug resistant bacterial Gram-negative infections.

Voulgaris GL, Voulgari ML, Falagas ME. Voulgaris GL, et al. Expert Rev Anti Infect Ther. 2019 Jun;17(6):387-401. doi: 10.1080/14787210.2019.1610392. Epub 2019 May 27. Expert Rev Anti Infect Ther. 2019. PMID: 31006284 Review.

5

Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens.

Karaiskos I, Galani I, Souli M, Giamarellou H. Karaiskos I, et al. Expert Opin Drug Metab Toxicol. 2019 Feb;15(2):133-149. doi: 10.1080/17425255.2019.1563071. Epub 2019 Jan 10. Expert Opin Drug Metab Toxicol. 2019. PMID: 30626244 Review.

6

Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.

Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, Idowu T, Domalaon R, Schweizer F, Zhanel MA, Lagacé-Wiens PRS, Walkty AJ, Noreddin A, Lynch Iii JP, Karlowsky JA. Zhanel GG, et al. Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2. Drugs. 2019. PMID: 30712199 Review.

7

Antibiotics in the clinical pipeline at the end of 2015.

Butler MS, Blaskovich MA, Cooper MA. Butler MS, et al. J Antibiot (Tokyo). 2017 Jan;70(1):3-24. doi: 10.1038/ja.2016.72. Epub 2016 Jun 29. J Antibiot (Tokyo). 2017. PMID: 27353164 Review.

8

[Recent progress in development of antibiotics against Gram-negative bacteria].

Xu ZQ, Xu ZY. Xu ZQ, et al. Yao Xue Xue Bao. 2013 Jul;48(7):993-1004. Yao Xue Xue Bao. 2013. PMID: 24133966 Review. Chinese.

9

Cephalosporins currently in early clinical trials for the treatment of bacterial infections.

Long TE, Williams JT. Long TE, et al. Expert Opin Investig Drugs. 2014 Oct;23(10):1375-87. doi: 10.1517/13543784.2014.930127. Epub 2014 Jun 23. Expert Opin Investig Drugs. 2014. PMID: 24956017 Review.

10

[New Antibiotics for Treatment of Highly Resistant Gram-negative Bacteria].

Probst-Kepper M, Geginat G. Probst-Kepper M, et al. Anasthesiol Intensivmed Notfallmed Schmerzther. 2018 Jul;53(7-08):529-542. doi: 10.1055/s-0043-110504. Epub 2018 Jul 23. Anasthesiol Intensivmed Notfallmed Schmerzther. 2018. PMID: 30036899 Review. German.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year